- Browse by Author
Browsing by Author "Frazee, Ashley"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Investigating the Modulation of Voltage-Gated Sodium Channel Nav1.1 Neuronal Excitability by Fibroblast Growth Factor Homologous Factor 2 and Il-6(2023-12) Frazee, Ashley; Cummins, Theodore; Berbari, Nicolas; Baucum, A.J.; Boehm, StephenMigraine is a condition that has affected many for generations and yet remains poorly understood. Mutations to the Nav1.1 voltage gated sodium channels have been implicated in various diseases such as Familial Hemiplegic Migraine 3 (FHM3), epilepsy, and autism spectrum disorder (ASD). Various proteins have been found to modify the function of these channels. Fibroblast growth factor homologous factors (FHFs) have been found to regulate the activity of some voltage-gated sodium channels (Navs). More work is needed to determine which FHFs affect which Navs. Here I looked at FHF2A and FHF2B in Nav1.1 as well as an FHM3-causing mutation to this channel, F1774S. I found that FHF2A, but not 2B, induced long-term inactivation (LTI) in the wild-type (WT) Nav1.1 and that FHF2A induced LTI in the F1774S mutant channel to a greater extent. Several changes in channel function caused by the mutation were attenuated with the addition of FHF2A, including persistent currents, leading to a possible rescue in the mutant phenotype. By contrast, the P1894L mutation, which has been found to cause ASD, greatly attenuated LTI and other impacts of FHF2A on Nav1.1. The inflammatory cytokine IL-6 was also investigated as a possible modulator of the Nav1.1 channel. There does not appear to be any direct interaction between this cytokine and the channel. Overall, my data shows for the first time that FHF2A, but FHF2B or IL-6, might be a significant modulator of Nav1.1 and can differentially modulate disease mutations.Item Modelling Nicotine Self-Administration Using Drinking-in-the-Dark(Office of the Vice Chancellor for Research, 2015-04-17) Frazee, Ashley; Kasten, Chelsea; Boehm, StephenAlthough cigarette smoking is a widely recognized problem in the United States, few animal models of nicotine self-administration exist. One aim of this study was to develop a new model of nicotine selfadministration in animals. The Drinking in Dark (DID) model, in which ethanol access is given for two hours, three hours into the dark cycle, can be easily altered to investigate nicotine intake and withdrawal. We found that animals will readily consume around 6 mg/kg of nicotine per day, which is equivalent to smoking approximately 3-4 cigarettes. A second aim of the study was to test pharmacological manipulations in the model. Two areas of focus for pharmaceutical manipulations involve GABA and acetylcholine. On the fifth day of nicotine DID we administered baclofen, a GABAB receptor agonist, or mecamylamine, a nicotinic acetylcholine receptor (nAChR) antagonist, immediately prior to nicotine consumption. We found that baclofen, but not mecamylamine, reduced nicotine intake (p < .05). The final aim of the study will be to test for face validity of the model. A separate group of mice will be given access to nicotine or saccharin for 5 or 10 days using DID procedures. Face validity of the model will be tested using the elevated plus maze and by observing locomotor activity during spontaneous withdrawal, approximately 55 hours following the last DID presentation. Taken together, these studies suggest that nicotine DID is a valid model of voluntary nicotine intake that can be tested for smoking treatments, as well as the neurobiological underpinnings of repeated nicotine use.